Clinical Trial of CD19 CAR-T Cell Therapy with non-virus Vector System

被引:0
|
作者
Takahashi, Yoshiyuki [1 ]
机构
[1] Nagoya Univ, Dept Pediat, Nagoya, Aichi, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SY5-1
引用
收藏
页码:S3 / S3
页数:1
相关论文
共 50 条
  • [21] Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy
    Jain, Michael D.
    Ziccheddu, Bachisio
    Coughlin, Caroline A.
    Faramand, Rawan
    Griswold, Anthony J.
    Reid, Kayla M.
    Landgren, Ola
    Locke, Frederick L.
    Maura, Francesco
    Davila, Marco L.
    Schatz, Jonathan H.
    BLOOD, 2021, 138
  • [22] CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report
    Sun, Zhuanyi
    Xie, Caiqin
    Liu, Hui
    Yuan, Xianggui
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
    Gong, Inna Y.
    Tran, Daisy
    Saibil, Samuel
    Laister, Rob C.
    Kuruvilla, John
    HEMASPHERE, 2024, 8 (08):
  • [24] Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy
    Chou, Cassie K.
    Turtle, Cameron J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 653 - 664
  • [25] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPY
    Jain, Michael
    Ziccheddu, Bachisio
    Coughlin, Caroline
    Faramand, Rawan
    Griswold, Anthony
    Reid, Kayla
    Landgren, Ola
    Locke, Frederick
    Maura, Francesco
    Davila, Marco
    Schatz, Jonathan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703
  • [26] Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
    Rejeski, Kai
    Perez, Ariel
    Iacoboni, Gloria
    Blumenberg, Viktoria
    Buecklein, Veit L.
    Voelkl, Simon
    Penack, Olaf
    Albanyan, Omar
    Stock, Sophia
    Mueller, Fabian
    Karschnia, Philipp
    Petrera, Agnese
    Reid, Kayla
    Faramand, Rawan
    Davila, Marco L.
    Modi, Karnav
    Dean, Erin A.
    Bachmeier, Christina
    von Bergwelt-Baildon, Michael
    Locke, Frederick L.
    Bethge, Wolfgang
    Bullinger, Lars
    Mackensen, Andreas
    Barba, Pere
    Jain, Michael D.
    Subklewe, Marion
    SCIENCE ADVANCES, 2023, 9 (38)
  • [27] Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
    Feng, Jingjing
    Hu, Yongxian
    Zhang, Mingming
    Cao, Heng
    Ke, Yini
    Xu, Huijun
    Cui, Jiazhen
    Zhang, Yanlei
    Chang, Alex Hongsheng
    Lin, Jin
    Wei, Guoqing
    Huang, He
    BLOOD, 2022, 140 : 10335 - 10336
  • [28] BsAbs before CD19 CAR-T full ahead!
    Riedell, Peter A.
    BLOOD, 2024, 144 (03) : 249 - 251
  • [29] Gammaretroviral Vector CD19 CAR-T Manufactured in the Cocoon® Platform: An Automated and Closed Workflow
    Purpura, Kelly A.
    Malka, Rivka Gal
    Jacoby, Elad
    Avigdor, Abraham
    Rodin, Anastasia
    Brayer, Hadar
    Morrissey-Scoot, James
    Fargo, Karen
    Vicentini-Hogan, Michele
    Ostrout, Nicholas
    Hewitt, Matthew
    Abraham, Eytan
    Trainor, Nuala
    Besser, Michal
    MOLECULAR THERAPY, 2021, 29 (04) : 416 - 416
  • [30] Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells
    Sharma, Ashish
    Roe, Anne
    Lopes, Filipa Blasco
    Liu, Ruifu
    Reese, Jane
    Ribeiro, Susan Pereira
    Sekaly, Rafick-Pierre
    de Lima, Marcos
    Wald, David
    BLOOD, 2018, 132